How does the Bdparp 100 mg tablet work in the body?

Bdparp 100mg tablet works by blocking the repair mechanism of DNA; as a result, the growth of cancer cells stops. The tablet inhibits PARP (poly-ADP-ribose polymerases), which belongs to the family of proteins that play an important role in genomic stability, DNA repair, and cellular stress responses. The enzymes repair the single-strand DNA breaks (SSBs). Bdparp 100 mg tablet inhibits the working of PARP enzymes, which hinders the growth and development of cancer cells.

If a person has low white blood cells (neutropenia), can they take a Bdparp 100 mg tablet?

A person with low white blood cells is advised to consult the doctor first before taking the Bdparp 100 mg tablet, as this drug can also cause neutropenia.

I forgot to take the Bdparp 100 mg tablet. What to do?

As soon as you remember, take the missed dose unless it's time for your next dose. You should never take a double dose to make up for a missed one.

What are the side effects of the Bdparp 100 mg tablet?

Common side effects of the Bdparp 100 mg tablet are constipation, muscle pain, swelling, nausea, diarrhea, infection, loss of appetite, hair loss, vomiting, and weakness.

How long does the treatment with the Bdparp 100 mg tablet last?

The doctor decides how long the treatment with the Bdparp 100 mg tablet will continue, depending on the stage and health of the patient

Can I drink alcohol while taking the Bdparp 100 mg tablet?

It is advised not to take alcohol while taking the Bdparp 100mg tablet, because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.

Is it safe to take this Bdparp 100 mg tablet during pregnancy or breastfeeding?

During pregnancy, it is not safe to take Bdparp 100 mg tablets, as they can cause harm to the unborn baby. Furthermore, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.

Deal of the Day — limited-time pharmacy picks!Deal of the Day — today's spotlight pharmacy prices, refreshed daily.

Bdparp 100mg Tablet

Name: Bdparp 100mg Tablet
Brand: Bdparp
Price: 15000 INR
Availability: InStock
Rating: 4.71 (7 reviews)

Rx Required

Salt Composition: Olaparib

Expiry Date: 01/2028

Price on Request

Inclusive of all taxes

▼

28 Tablets in Bottle

About The Product

Ovarian Cancer, Breast Cancer

Bdparp 100mg tablet contains olaparib, which belongs to the antiviral drug category polyadenosine diphosphate-ribose polymerase (PARP). In cancer cells multiply in an uncontrolled manner. This tablet is used for treating prostate and pancreatic cancer; it can be given alone or in combination with other anticancer medications.

Uses

Audeh, M.
W., Carmichael, J., Penson, R.
T., Friedlander, M., Powell, B., Bell-McGuinn, K.
M., & Tutt, A.
(2020).
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
The Lancet, 376(9737), 245-251.
Guo, X.
X., Wu, H.
L., Shi, H.
Y., Su, L., & Zhang, X.
(2024).
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
Cancer Management and Research, 2553-2562.
Tutt, A., Robson, M., Garber, J.
E., Domchek, S.
M., Audeh, M.
W., Weitzel, J.
N. & Carmichael, J.
(2020).
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
The Lancet, 376(9737), 235-244. van der Noll, R., Jager, A., Ang, J.
E., Marchetti, S., Mergui-Roelvink, M.
W., de Bono, J.
S., & Schellens, J.
H.
(2020).
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Investigational New Drugs, 38(4), 1096-1107.
Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T.
(2020).
A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
Cancer science, 103(3), 504-509.

Benefits

Audeh, M. W., Carmichael, J., Penson, R.

T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A.

(2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

The Lancet, 376(9737), 245-251. Guo, X.

X., Wu, H. L., Shi, H.

Y., Su, L., & Zhang, X. (2024).

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S.

M., Audeh, M. W., Weitzel, J.

N. & Carmichael, J. (2020).

Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244. van der Noll, R., Jager, A., Ang, J.

E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J.

S., & Schellens, J. H.

(2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).

Investigational New Drugs, 38(4), 1096-1107. Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T.

(2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

Cancer science, 103(3), 504-509.

Side Effects

Audeh, M.
W., Carmichael, J., Penson, R.
T., Friedlander, M., Powell, B., Bell-McGuinn, K.
M., & Tutt, A.
(2020).
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
The Lancet, 376(9737), 245-251.
Guo, X.
X., Wu, H.
L., Shi, H.
Y., Su, L., & Zhang, X.
(2024).
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
Cancer Management and Research, 2553-2562.
Tutt, A., Robson, M., Garber, J.
E., Domchek, S.
M., Audeh, M.
W., Weitzel, J.
N. & Carmichael, J.
(2020).
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
The Lancet, 376(9737), 235-244. van der Noll, R., Jager, A., Ang, J.
E., Marchetti, S., Mergui-Roelvink, M.
W., de Bono, J.
S., & Schellens, J.
H.
(2020).
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Investigational New Drugs, 38(4), 1096-1107.
Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T.
(2020).
A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
Cancer science, 103(3), 504-509.

How To Use

Audeh, M.
W., Carmichael, J., Penson, R.
T., Friedlander, M., Powell, B., Bell-McGuinn, K.
M., & Tutt, A.
(2020).
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
The Lancet, 376(9737), 245-251.
Guo, X.
X., Wu, H.
L., Shi, H.
Y., Su, L., & Zhang, X.
(2024).
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
Cancer Management and Research, 2553-2562.
Tutt, A., Robson, M., Garber, J.
E., Domchek, S.
M., Audeh, M.
W., Weitzel, J.
N. & Carmichael, J.
(2020).
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
The Lancet, 376(9737), 235-244. van der Noll, R., Jager, A., Ang, J.
E., Marchetti, S., Mergui-Roelvink, M.
W., de Bono, J.
S., & Schellens, J.
H.
(2020).
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Investigational New Drugs, 38(4), 1096-1107.
Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T.
(2020).
A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
Cancer science, 103(3), 504-509.

How It Works

Audeh, M. W., Carmichael, J., Penson, R.

T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A.

(2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

The Lancet, 376(9737), 245-251. Guo, X.

X., Wu, H. L., Shi, H.

Y., Su, L., & Zhang, X. (2024).

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S.

M., Audeh, M. W., Weitzel, J.

N. & Carmichael, J. (2020).

E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J.

S., & Schellens, J. H.

(2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).

Investigational New Drugs, 38(4), 1096-1107. Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T.

(2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

Cancer science, 103(3), 504-509.

Safety Advice

Alcohol

Drinking too much alcohol could damage a person's immunity and liver function. Alcohol consumption can cause dizziness, confusion, tiredness, and cognitive impairment, so it is advised not to consume alcohol while taking the Bdparp 100mg tablet.

Pregnancy

It is not advised to take the Bdparp 100mg tablet when pregnant because it affects the fetus. This is not for use in pregnant women.

Breast Feeding

Because there is a possibility that the Bdparp 100 mg tablet could be transferred to the developing infant through the mother's breast milk, it is not advised to consume it while nursing. It is widely regarded as dangerous, and there is not enough evidence in the clinical data on its adverse impacts on infants.

Driving

Taking a Bdparp 100 mg tablet while operating machinery may cause confusion or impair one's driving capacity. The capsule may cause neurological side effects, such as fever or feeling dizzy. Until you feel better, don't drive.

Kidney

People with kidney issues can use the Bdparp 100 mg tablet after consulting with the doctor. It may harm the kidneys if taken as self-medication

Liver

People with severe liver illness should not use the Bdparp 100 mg tablet. Whereas people with mild liver disease can use this solution, but it must be regularly monitored. Use caution and alter the dosage of the Bdparp 100 mg tablet as advised by your doctor.

FAQs

Bdparp 100 mg tablet is used for the treatment of breast, ovarian, prostate, and pancreatic cancer.

Reference

Audeh, M. W., Carmichael, J., Penson, R.

T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A.

(2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

The Lancet, 376(9737), 245-251. Guo, X.

X., Wu, H. L., Shi, H.

Y., Su, L., & Zhang, X. (2024).

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S.

M., Audeh, M. W., Weitzel, J.

N. & Carmichael, J. (2020).

E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J.

S., & Schellens, J. H.

(2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).

Investigational New Drugs, 38(4), 1096-1107. Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T.

(2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

Cancer science, 103(3), 504-509.

Last updated: 5 Aug 2026 | 04:33 PM (IST)

Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only

Not a substitute for professional medical advice

Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.

Read full medical disclaimer in Terms & Conditions